INTUITIVE SURGICAL INC Q2 FY2025 earnings call

Management Statement and Operational Highlights

• Acknowledged Gary Guthart's transition to Executive Chair of the Board. Discussed strong financial metrics in Q2 with 21% revenue growth, pro forma operating margin 39%, and pro forma earnings per share up 23%.
• Highlighted da Vinci 5 broad launch in the US, with clearances in Europe and Japan. SP procedures grew 88% year-over-year, and Ion procedures grew 52%.
• Emphasized digital ecosystem advancements like Intuitive Telepresence and the importance of cybersecurity/privacy for telesurgery. Focused on the Quintuple Aim of better patient outcomes, experiences, and lower costs.
• Mentioned clinical studies, including a JAMA study on robotic vs. laparoscopic surgery for rectal cancer showing lower local regional recurrence with robotic surgery.

Segment Performance

• Da Vinci: Procedures grew 17%. Installed base of da Vinci systems increased 14% to almost 10,500 globally, average system utilization rose 2%.
• SP: Procedures grew 88% year-over-year. Placed 23 SP systems in Q2. Utilization rose 30%.
• Ion: Procedures grew 52% to approximately 35,000. Placed 54 Ion systems. Installed base expanded to 905, average system utilization increased 8%.

Guidance

• Updated da Vinci procedure growth guidance for 2025 to 15.5%-17%.
• Pro forma gross margin expected to be 66%-67% of revenue.
• Pro forma operating expense growth expected between 10%-14%.
• Other income expected to total $370M-$390M.
• Capital expenditures estimated at $650M-$725M.
• Pro forma income tax rate expected to be 22%-23% of pretax income.

Risks

• Macro challenges in certain international markets, including government budget constraints in Japan, China, and Europe.
• Uncertainty around Medicaid coverage in the US, potentially impacting patient access to care.
• Trade environment and tariff impacts, with tariffs expected to increase cost of sales by ~1% of revenue.
• Supply constraints for force feedback instruments, expected to continue through Q1 next year.

Question and Answer Q: Margin question and reprocessing.

A: Jamie noted strong revenue growth, purchase mix impact, and operating margin result not as new normal. Dave discussed customers evaluating remanufactured instruments via value committees, emphasizing high-quality instruments and innovation.

Q: Medicaid policy and capital side.

A: Jamie said it's early to comment on Medicaid impact, but US system placements were solid with growth in US and challenges internationally. Dave discussed trade-ins and da Vinci 5 clearance in Europe/Japan.

Q: Force feedback launch update.

A: Unidentified rep said supply constrained through Q1 next year, pleased with adoption. Jamie mentioned Force Feedback as a small component of I&A per procedure.

Q: System placements outside US and trade-ins.

A: Jamie said measured rollout for da Vinci 5 in Europe/Japan, trade-ins in US give opportunity for XIR in portfolio.

Q: Robotics in new spaces.

A: Dave discussed ASC and outpatient environments, emphasizing reliable technology for surgeons.

Q: Da Vinci 5 evolution.

A: Dave talked about ongoing feature enhancements and their impact on adoption/utilization.

Q: Curve vessel sealer impact.

A: Jamie said the device has a slimmer profile, suited for narrow spaces, enhancing penetration in certain procedures with minor impact on I&A per procedure.